ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis

[1]  T. Silhavy,et al.  Genomic and Biochemical Insights into the Specificity of ETS Transcription Factors , 2017 .

[2]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[3]  Hamid Bolouri,et al.  Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer , 2016 .

[4]  Joshua M. Stuart,et al.  A basal stem cell signature identifies aggressive prostate cancer phenotypes , 2015, Proceedings of the National Academy of Sciences.

[5]  Henry W. Long,et al.  The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis , 2015, Nature Genetics.

[6]  D. Zheng,et al.  Significant expansion of the REST/NRSF cistrome in human versus mouse embryonic stem cells: potential implications for neural development , 2015, Nucleic acids research.

[7]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[8]  Joshua M. Korn,et al.  TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation , 2014, Oncogene.

[9]  E. Cuppen,et al.  Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures , 2014, Cell.

[10]  Hans Clevers,et al.  Organoid Cultures Derived from Patients with Advanced Prostate Cancer , 2014, Cell.

[11]  Douglas E. V. Pires,et al.  DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach , 2014, Nucleic Acids Res..

[12]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[13]  Christof Fellmann,et al.  An optimized microRNA backbone for effective single-copy RNAi. , 2013, Cell reports.

[14]  D. Zheng,et al.  Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade , 2013, Cell.

[15]  John H. Bushweller,et al.  Structural and dynamic studies of the transcription factor ERG reveal DNA binding is allosterically autoinhibited , 2013, Proceedings of the National Academy of Sciences.

[16]  D. Zheng,et al.  ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss , 2013, Nature Medicine.

[17]  V. Arora,et al.  Overcoming mutation-based resistance to antiandrogens with rational drug design , 2013, eLife.

[18]  S. Knight,et al.  Reduced dosage of ERF causes complex craniosynostosis in humans and mice and links ERK1/2 signaling to regulation of osteogenesis , 2013, Nature Genetics.

[19]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[20]  Yong Zhang,et al.  Identifying ChIP-seq enrichment using MACS , 2012, Nature Protocols.

[21]  Philip Machanick,et al.  MEME-ChIP: motif analysis of large DNA datasets , 2011, Bioinform..

[22]  Tao Ye,et al.  seqMINER: an integrated ChIP-seq data interpretation platform , 2010, Nucleic acids research.

[23]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[24]  M. Ittmann,et al.  Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. , 2008, Cancer research.

[25]  P. Nelson,et al.  A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.

[26]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[27]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[28]  Myles A Brown,et al.  Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. , 2005, Molecular cell.

[29]  Biaoyang Lin,et al.  The program of androgen-responsive genes in neoplastic prostate epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. J. Fisher,et al.  ERF: an ETS domain protein with strong transcriptional repressor activity, can suppress ets‐associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation. , 1995, The EMBO journal.